Husseini Manji

Johnson & Johnson (NYSE: JNJ) received encouraging news after a FDA panel decision went its way with respect to its treatment-resistant depression drug. Panel Finds Risk-Benefit Favorable A joint committee of the FDA's Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk...